Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Medical Care Research and Review : MCRR|April 21, 2004
Pharmacy data in the VA health care systemMark W Smith, George J JosephJournal of Medical Economics|July 2, 2013
Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitisMachaon Bonafede, George J Joseph, Nicole Princic, et al.Clinicoeconomics and Outcomes Research : CEOR|September 24, 2014
Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid populationMachaon Bonafede, George J Joseph, Neel Shah, et al.Effective Clinical Practice : ECP|August 9, 2002
Using the Veterans Health Administration inpatient care database: trends in the use of antireflux surgerySamuel R G Finalyson, Kevin T Stroupe, George J Joseph, et al.Journal of Medical Economics|September 8, 2016
Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United StatesDominick Latremouille-Viau, Annie Guerin, Roy Nitulescu, et al.Journal of Managed Care Pharmacy : JMCP|October 1, 2013
Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care populationVernon F Schabert, Crystal Watson, George J Joseph, et al.Journal of Managed Care & Specialty Pharmacy|January 27, 2017
Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring FrequencyDominick Latremouille-Viau, Annie Guerin, Patrick Gagnon-Sanschagrin, et al.Journal of Medical Economics|January 19, 2021
Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United StatesMichael L Volk, Rebecca Burne, Annie Guérin, et al.Clinical and Experimental Rheumatology|March 5, 2015
Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2)Allan Gibofsky, Grant W Cannon, David J Harrison, et al.Leukemia & Lymphoma|January 23, 2019
Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspectiveEllen K Ritchie, Dominick Latremouille-Viau, Annie Guerin, et al.Pageof 3